Glenmark Pharmaceuticals Ltd
NSE :GLENMARK BSE :532296 Sector : PharmaceuticalsBuy, Sell or Hold GLENMARK? Ask The Analyst
BSE
prev close
OPEN PRICE
volume
Today's low / high
52 WK low / high
bid price (qty)
offer price (qty)
NSE
prev close
open price
volume
Today's' low / high
52 WK low / high
bid price (qty)
offer price (qty)
14 Jan 1515.95 (1.27%) | 13 Jan 1496.90 (-2.91%) | 10 Jan 1541.70 (-3.24%) | 09 Jan 1593.30 (-2.13%) | 08 Jan 1627.90 (-0.86%) | 07 Jan 1642.05 (1.13%) | 06 Jan 1623.75 (-0.75%) | 03 Jan 1636.10 (-0.20%) | 02 Jan 1639.35 (1.54%) | 01 Jan 1614.50 (0.34%) | 31 Dec 1609.10 (1.21%) | 30 Dec 1589.80 (0.24%) | 27 Dec 1585.95 (2.89%) | 26 Dec 1541.45 (0.37%) | 24 Dec 1535.80 (-0.95%) | 23 Dec 1550.60 (0.58%) | 20 Dec 1541.65 (0.06%) | 19 Dec 1540.80 (1.06%) | 18 Dec 1524.70 (0.70%) | 17 Dec 1514.10 (-2.40%) | 16 Dec 1551.35 (2.19%) |
Price Chart Historical Data Technical Chart
Technical Analysis
Short Term Investors
Very Bearish
Medium Term Investors
Neutral
Long Term Investors
Bullish
Moving Averages
5 DMA
Bearish
1554.55
10 DMA
Bearish
1592.58
20 DMA
Bearish
1572.8
50 DMA
Bearish
1566.87
100 DMA
Bearish
1636.62
200 DMA
Bullish
1425.19
Intraday Support and Resistance
(Based on Pivot Points) |
Updated On Jan 14, 2025 04:00 PM For Next Trading Session
Pivots | Classic | Fibonacci | Camarilla | Woodie | DM |
---|---|---|---|---|---|
R3 | 1582.3 | 1555.15 | 1528.81 | - | - |
R2 | 1555.15 | 1537.29 | 1524.52 | 1557.04 | - |
R1 | 1535.55 | 1526.26 | 1520.24 | 1539.33 | 1545.35 |
P | 1508.4 | 1508.4 | 1508.4 | 1510.29 | 1513.3 |
S1 | 1488.8 | 1490.54 | 1511.66 | 1492.58 | 1498.6 |
S2 | 1461.65 | 1479.51 | 1507.38 | 1463.54 | - |
S3 | 1442.05 | 1461.65 | 1503.09 | - | - |
Key Metrics
EPS
67.15
P/E
22.56
P/B
1.79
Dividend Yield
0.17%
Market Cap
42,778 Cr.
Face Value
1
Book Value
848.58
ROE
-50.87%
EBITDA Growth
640.33 Cr.
Debt/Equity
0.34
Shareholding History
Quarterly Result (Figures in Rs. Crores)
Glenmark Pharmaceuticals Ltd Quaterly Results
Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | ||
INCOME | 3327.81 | 2670.88 | 3860.49 | 3275.68 | 3473.21 | |
PROFIT | 68.79 | -393.41 | -2285.2 | 340.27 | 354.21 | |
EPS | -2.9 | -12.45 | -43.17 | 12.06 | 12.55 |
Glenmark Pharmaceuticals Ltd Quaterly Results
Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | ||
INCOME | 2306.99 | 1623.91 | 8081.41 | 2385.19 | 2719.18 | |
PROFIT | 317.62 | 4.87 | 841.36 | 453.73 | 595.06 | |
EPS | 10.72 | -0.72 | 163.5 | 16.08 | 21.09 |
Profit & Loss (Figures in Rs. Crores)
Glenmark Pharmaceuticals Ltd Profit & Loss
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | ||
INCOME | 6943.01 | 7721.83 | 9576.39 | 9032.11 | 10299.46 | 10705.37 | 11227.94 | 12482.71 | 12579.76 | 13246.04 | |
PROFIT | 263.52 | 743.05 | 1155.03 | 805.34 | 818.68 | 755.72 | 941.32 | 1107.67 | 609.68 | -4473.72 | |
EPS | 7.3 | 26.33 | 39.29 | 28.49 | 32.78 | 27.5 | 34.38 | 35.21 | 13.37 | -50.8 |
Glenmark Pharmaceuticals Ltd Profit & Loss
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | ||
INCOME | 5358.49 | 6306 | 8220.99 | 5709.21 | 6787.67 | 7289.2 | 8032.82 | 9202.67 | 9237.97 | 14232.55 | |
PROFIT | 1139.79 | 1484.9 | 2322 | 1016.26 | 1344.95 | 1340.12 | 1589.58 | 1643.77 | 1578.33 | 1425.03 | |
EPS | 36.72 | 52.6 | 75.86 | 35.95 | 57.49 | 48 | 58.46 | 70.8 | 42.84 | 183.11 |
Balance Sheet (Figures in Rs. Crores)
Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | |
SOURCES OF FUNDS : | ||||||||||
Share Capital | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 27.13 |
Reserves Total | 7,819.71 | 9,445.71 | 9,058.43 | 7,036.41 | 6,042.29 | 5,576.97 | 5,135.26 | 4,464.31 | 3,601.42 | 1,756.36 |
Total Shareholders Funds | 7,847.93 | 9,473.93 | 9,086.65 | 7,064.63 | 6,070.51 | 5,605.19 | 5,163.48 | 4,492.53 | 3,629.64 | 1,783.49 |
Minority Interest | -0.38 | 365.34 | 351.47 | -0.35 | -0.39 | -0.38 | -0.37 | -0.42 | -0.3 | -0.19 |
Secured Loans | 0 | 0 | 0 | 0 | 0 | 6.11 | 19.74 | 2.59 | 15.53 | 36.69 |
Unsecured Loans | 1,230.93 | 4,607.88 | 3,962.02 | 4,985.72 | 4,868.63 | 4,442.56 | 4,619.64 | 4,721.06 | 3,972.58 | 3,763.24 |
Total Debt | 1,230.93 | 4,607.88 | 3,962.02 | 4,985.72 | 4,868.63 | 4,448.67 | 4,639.38 | 4,723.65 | 3,988.11 | 3,799.93 |
Other Liabilities | 540.52 | 397.59 | 152.5 | 196.68 | 429.27 | 89.14 | 2.6 | 32.74 | 76.99 | 121.92 |
Total Liabilities | 9,619 | 14,844.74 | 13,552.64 | 12,246.68 | 11,368.02 | 10,142.62 | 9,805.09 | 9,248.5 | 7,694.44 | 5,705.15 |
APPLICATION OF FUNDS : | ||||||||||
Gross Block | 9,619.64 | 10,359.59 | 10,213.47 | 8,731.58 | 8,269.83 | 6,527.27 | 5,367.95 | 4,769.92 | 4,300.54 | 3,495.47 |
Less: Accumulated Depreciation | 5,409.48 | 4,937.83 | 4,326.23 | 3,602.73 | 3,241.28 | 2,857.01 | 2,338.4 | 2,014.83 | 1,706.99 | 1,480.09 |
Net Block | 4,210.16 | 5,421.76 | 5,887.24 | 5,128.85 | 5,028.55 | 3,670.26 | 3,029.55 | 2,755.09 | 2,593.55 | 2,015.38 |
Capital Work in Progress | 661.88 | 1,189.64 | 1,009.87 | 1,381.67 | 1,221.89 | 1,398.94 | 1,121.87 | 708.11 | 542.8 | 477.13 |
Investments | 789.66 | 44.57 | 49.62 | 24.63 | 24.59 | 29.66 | 14.66 | 15.69 | 17.2 | 17.12 |
Inventories | 2,513.05 | 2,373.62 | 2,499.83 | 2,276.83 | 2,135.62 | 2,252.07 | 2,030.59 | 2,139.05 | 1,567.76 | 1,269.04 |
Sundry Debtors | 1,858.41 | 3,665.17 | 3,101.14 | 2,572.06 | 2,408.96 | 2,194.59 | 2,331.81 | 2,404.32 | 2,492.65 | 2,511.77 |
Cash and Bank Balance | 1,659.46 | 1,160.3 | 1,411.52 | 1,139.16 | 1,111.24 | 937.77 | 1,234.69 | 1,057.66 | 857.12 | 775.88 |
Loans and Advances | 1,397.17 | 3,526.44 | 1,269.87 | 1,371.54 | 1,147.78 | 1,312.4 | 1,391.61 | 1,273.61 | 986.77 | 774.38 |
Total Current Assets | 7,428.08 | 10,725.53 | 8,282.35 | 7,359.58 | 6,803.61 | 6,696.83 | 6,988.69 | 6,874.64 | 5,904.3 | 5,331.07 |
Current Liabilities | 3,807.27 | 3,935.93 | 2,914.64 | 2,763.7 | 2,744.43 | 2,662.08 | 2,357.82 | 2,252.41 | 2,364.42 | 2,334.38 |
Provisions | 932.08 | 590.51 | 584.5 | 564.45 | 555.91 | 484.11 | 432.46 | 262.95 | 134.03 | 216.78 |
Total Current Liabilities & Provisions | 4,739.35 | 4,526.44 | 3,499.14 | 3,328.16 | 3,300.34 | 3,146.18 | 2,790.28 | 2,515.36 | 2,498.44 | 2,551.16 |
Net Current Assets | 2,688.74 | 6,199.09 | 4,783.21 | 4,031.42 | 3,503.27 | 3,550.65 | 4,198.41 | 4,359.27 | 3,405.86 | 2,779.91 |
Deferred Tax Assets | 1,049.72 | 1,805.91 | 1,969.55 | 1,852.18 | 1,770.85 | 1,761.63 | 1,728.58 | 1,553.35 | 1,274.96 | 169.73 |
Deferred Tax Liability | 0.28 | 0.51 | 314.93 | 346.26 | 331.59 | 378.68 | 408.32 | 242.08 | 210.07 | 222.52 |
Net Deferred Tax | 1,049.44 | 1,805.4 | 1,654.62 | 1,505.92 | 1,439.26 | 1,382.95 | 1,320.26 | 1,311.27 | 1,064.89 | -52.79 |
Other Assets | 219.11 | 184.27 | 168.08 | 174.18 | 150.45 | 110.16 | 120.34 | 99.06 | 70.15 | 468.42 |
Total Assets | 9,618.99 | 14,844.73 | 13,552.65 | 12,246.67 | 11,368.01 | 10,142.61 | 9,805.09 | 9,248.49 | 7,694.44 | 5,705.16 |
Contingent Liabilities | 1,063.3 | 336.69 | 361.31 | 384.2 | 271.21 | 73.51 | 47.1 | 36.88 | 36.89 | 129.37 |
Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | |
SOURCES OF FUNDS : | ||||||||||
Share Capital | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 27.13 |
Reserves Total | 22,942.4 | 17,849.25 | 16,710.37 | 14,781.29 | 13,198.05 | 11,913.87 | 10,363.22 | 9,408.4 | 7,337.75 | 4,924.92 |
Total Shareholders Funds | 22,970.62 | 17,877.47 | 16,738.59 | 14,809.51 | 13,226.27 | 11,942.09 | 10,391.44 | 9,436.62 | 7,365.97 | 4,952.05 |
Secured Loans | 0 | 0 | 0 | 0 | 0 | 6.11 | 19.74 | 2.59 | 15.53 | 36.69 |
Unsecured Loans | 707.29 | 3,221.22 | 3,737.7 | 3,703.99 | 3,573.76 | 3,128.37 | 2,961.33 | 2,773.94 | 771.89 | 373.41 |
Total Debt | 707.29 | 3,221.22 | 3,737.7 | 3,703.99 | 3,573.76 | 3,134.48 | 2,981.07 | 2,776.53 | 787.42 | 410.1 |
Other Liabilities | 131.94 | 372.58 | 121.32 | 136.61 | 205.65 | 88.51 | 2.6 | 2.41 | 4.7 | 121.92 |
Total Liabilities | 23,809.85 | 21,471.27 | 20,597.61 | 18,650.11 | 17,005.68 | 15,165.08 | 13,375.11 | 12,215.56 | 8,158.09 | 5,484.07 |
APPLICATION OF FUNDS : | ||||||||||
Gross Block | 3,392.75 | 3,183.65 | 3,026.28 | 2,848.56 | 2,595.06 | 2,260.1 | 2,581.75 | 2,368.53 | 2,107.04 | 1,801.98 |
Less : Accumulated Depreciation | 1,636.5 | 1,437.7 | 1,273.95 | 1,126.07 | 983.11 | 846.62 | 882.63 | 772.16 | 669.04 | 571.3 |
Net Block | 1,756.25 | 1,745.95 | 1,752.33 | 1,722.49 | 1,611.95 | 1,413.48 | 1,699.12 | 1,596.37 | 1,438 | 1,230.68 |
Capital Work in Progress | 197.67 | 172.34 | 109.04 | 131.4 | 200.01 | 286.2 | 419.68 | 270.66 | 276.06 | 294.19 |
Investments | 12,964.79 | 10,332.71 | 8,559.39 | 6,989.95 | 4,713.93 | 3,268.75 | 3,212.68 | 1,866.7 | 1,858.43 | 1,659.52 |
Inventories | 1,142.69 | 1,090.21 | 951.66 | 762.39 | 837.5 | 911.21 | 1,111.18 | 1,145.06 | 968 | 736.63 |
Sundry Debtors | 2,484.47 | 2,505.66 | 2,678.32 | 2,488.75 | 1,835.24 | 2,087.13 | 3,828.91 | 3,879.4 | 3,057.66 | 2,440.83 |
Cash and Bank Balance | 129.15 | 93.79 | 29.63 | 15.79 | 88.26 | 256.48 | 177.38 | 252.18 | 74.24 | 48.55 |
Loans and Advances | 925.17 | 696.82 | 743.31 | 1,642.2 | 1,662.89 | 1,886.33 | 757.78 | 674.19 | 528.03 | 371.94 |
Total Current Assets | 4,681.48 | 4,386.48 | 4,402.93 | 4,909.12 | 4,423.89 | 5,141.15 | 5,875.25 | 5,950.83 | 4,627.93 | 3,597.95 |
Current Liabilities | 3,249.79 | 2,952.14 | 2,168.39 | 1,834.31 | 1,827.48 | 1,855.86 | 1,796.56 | 1,727.02 | 1,867.56 | 1,882.99 |
Provisions | 354.74 | 162.52 | 148.49 | 133.11 | 118.45 | 121.75 | 93.2 | 57.97 | 87.37 | 151.38 |
Total Current Liabilities & Provisions | 3,604.54 | 3,114.66 | 2,316.88 | 1,967.41 | 1,945.92 | 1,977.62 | 1,889.76 | 1,784.98 | 1,954.93 | 2,034.37 |
Net Current Assets | 1,076.94 | 1,271.82 | 2,086.05 | 2,941.71 | 2,477.97 | 3,163.54 | 3,985.49 | 4,165.85 | 2,672.99 | 1,563.58 |
Deferred Tax Assets | 475.61 | 1,160.25 | 1,137.47 | 1,118.72 | 1,081.34 | 1,063.23 | 1,056.45 | 820.62 | 589.41 | 24.84 |
Deferred Tax Liability | 309.77 | 213.5 | 214.2 | 265.43 | 276.6 | 351.1 | 395.83 | 226.56 | 188.25 | 157.23 |
Net Deferred Tax | 165.84 | 946.75 | 923.27 | 853.29 | 804.74 | 712.13 | 660.62 | 594.06 | 401.16 | -132.39 |
Other Assets | 7,648.37 | 7,001.7 | 7,167.54 | 6,011.27 | 7,197.08 | 6,320.98 | 3,397.52 | 3,721.92 | 1,511.43 | 868.49 |
Total Assets | 23,809.85 | 21,471.26 | 20,597.62 | 18,650.11 | 17,005.68 | 15,165.08 | 13,375.11 | 12,215.56 | 8,158.08 | 5,484.07 |
Contingent Liabilities | 2,658.49 | 3,443.3 | 3,325.06 | 3,730.17 | 4,430.59 | 3,680.94 | 4,549.6 | 3,720.76 | 4,594.01 | 5,326.65 |
Cash Flow (Figures in Rs. Crores)
Net Profit before Tax and Extr... | 569.19 |
Depreciation | 630.81 |
Interest (Net) | 500.14 |
P/L on Sales of Assets | -0.83 |
P/L on Sales of Invest | -7.05 |
Prov. and W/O (Net) | 68.38 |
P/L in Forex | -342.59 |
Total Adjustments (PBT and Ext... | 1,009.81 |
Operating Profit before Workin... | 1,579 |
Trade and 0ther Receivables | 969.51 |
Inventories | -513.86 |
Trade Payables | -734.41 |
Total Adjustments (OP before W... | -796.95 |
Cash Generated from/(used in) ... | 782.05 |
Direct Taxes Paid | -1,047.49 |
Total Adjustments(Cash Generat... | -1,047.49 |
Cash Flow before Extraordinary... | -265.44 |
Net Cash from Operating Activi... | -265.44 |
Purchased of Fixed Assets | -898.38 |
Sale of Fixed Assets | 2.08 |
Sale of Investments | 7.05 |
Interest Received | 17.16 |
Cancellation of Investment in ... | 5,449.61 |
Net Cash used in Investing Act... | 4,386.82 |
Proceeds from Issue of shares ... | 1.2 |
Proceed from Short Tem Borrowi... | 481.12 |
Of the Long Tem Borrowings | -3,649.49 |
Of Financial Liabilities | -104.43 |
Dividend Paid | -117.75 |
Interest Paid | -516.78 |
Net Cash used in Financing Act... | -3,906.13 |
Net Profit before Tax and Extr... | 7,000.75 |
Depreciation | 202.16 |
Interest (Net) | 103.58 |
Dividend Received | 228.39 |
P/L on Sales of Assets | 0.25 |
P/L on Sales of Invest | -7.05 |
Prov. and W/O (Net) | 33.39 |
P/L in Forex | -173.41 |
Total Adjustments (PBT and Ext... | -5,884.79 |
Operating Profit before Workin... | 1,115.96 |
Trade and 0ther Receivables | -63.2 |
Inventories | -147.52 |
Trade Payables | -272.03 |
Total Adjustments (OP before W... | -740.31 |
Cash Generated from/(used in) ... | 375.65 |
Direct Taxes Paid | -871.1 |
Total Adjustments(Cash Generat... | -871.1 |
Cash Flow before Extraordinary... | -495.45 |
Net Cash from Operating Activi... | -495.45 |
Purchased of Fixed Assets | -195.11 |
Sale of Fixed Assets | 0.5 |
Sale of Investments | 7.05 |
Interest Received | 278.45 |
Invest.In Subsidiaires | -9.05 |
Loans to Subsidiaires | -2,562.51 |
Cancellation of Investment in ... | 5,449.61 |
Net Cash used in Investing Act... | 3,197.17 |
Proceeds from Issue of shares ... | 1.2 |
Proceed from Short Tem Borrowi... | 150 |
Of the Long Tem Borrowings | -2,449.18 |
Of Financial Liabilities | -35.63 |
Dividend Paid | -70.45 |
Interest Paid | -262.39 |
Net Cash used in Financing Act... | -2,666.45 |
Company Details
Registered Office |
|
Address | B/2 Mahalaxmi Chambers, 22 Bhulabhai Desai Road |
City | Mumbai |
State | Maharashtra |
Pin Code | 400026 |
Tel. No. | 91-22-40189999 |
Fax. No. | 91-22-40189986 |
complianceofficer@glenmarkpharma.com | |
Internet | http://www.glenmarkpharma.com |
Registrars |
|
Address | B/2 Mahalaxmi Chambers |
City | Mumbai |
State | Maharashtra |
Pin Code | 400026 |
Tel. No. | 91-22-40189999 |
Fax. No. | 91-22-40189986 |
complianceofficer@glenmarkpharma.com | |
Internet | http://www.glenmarkpharma.com |
Management |
|
Name | Designation |
Glenn Saldanha | Chairman & Managing Director |
Cheryl Pinto | Executive Director (Corporate) |
V S Mani | Executive Director & Group CFO |
B E Saldanha | Non Executive Director |
Rajesh Desai. | Independent Non Exe. Director |
Sona Saira Ramasastry | Independent Non Exe. Director |
Dipankar Bhattacharjee | Independent Non Exe. Director |
V R Iyer | Independent Non Exe. Director |